AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

Search

GlaxoSmithKline PLC

Geschlossen

BrancheGesundheitswesen

1,398 2.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1363

Max

1403

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.3B

1.8B

Verkäufe

-601M

7.5B

KGV

Branchendurchschnitt

18.415

56.602

EPS

44.9

Dividendenrendite

4.65

Gewinnspanne

23.576

Angestellte

68,629

EBITDA

2B

3.1B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+2.96% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.65%

2.45%

Nächstes Ergebnis

30. Juli 2025

Nächste Dividendenausschüttung

10. Juli 2025

Nächstes Ex-Dividendendatum

14. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-174M

57B

Vorheriger Eröffnungskurs

1395.39

Vorheriger Schlusskurs

1398

Nachrichtenstimmung

By Acuity

43%

57%

150 / 382 Ranking in Healthcare

GlaxoSmithKline PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Mai 2025, 11:01 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14. Mai 2025, 06:39 UTC

Akquisitionen, Fusionen, Übernahmen

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12. Mai 2025, 09:36 UTC

Wichtige Markttreiber

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30. Apr. 2025, 07:03 UTC

Ergebnisse

GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs -- Update

30. Apr. 2025, 06:37 UTC

Ergebnisse

GSK Sales, Profit Rise on Boost from Cancer Drugs

15. Mai 2025, 15:20 UTC

Top News

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14. Mai 2025, 06:08 UTC

Akquisitionen, Fusionen, Übernahmen

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14. Mai 2025, 06:03 UTC

Akquisitionen, Fusionen, Übernahmen

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14. Mai 2025, 06:03 UTC

Akquisitionen, Fusionen, Übernahmen

GSK PLC to Pay $1.2B Upfront

14. Mai 2025, 06:03 UTC

Akquisitionen, Fusionen, Übernahmen

GSK to Buy Efimosfermin for up to $2B

14. Mai 2025, 06:00 UTC

Akquisitionen, Fusionen, Übernahmen

GSK to Buy Efimosfermin

12. Mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. Mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30. Apr. 2025, 08:54 UTC

Market Talk
Ergebnisse

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30. Apr. 2025, 07:49 UTC

Market Talk
Ergebnisse

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30. Apr. 2025, 07:06 UTC

Market Talk
Ergebnisse

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

30. Apr. 2025, 06:03 UTC

Ergebnisse

GSK: Confident in Long-Term Outlook

30. Apr. 2025, 06:03 UTC

Ergebnisse

GSK Declares Dividend of 16p Vs 15p

30. Apr. 2025, 06:02 UTC

Ergebnisse

GSK 1Q Core EPS 44.9p

30. Apr. 2025, 06:02 UTC

Ergebnisse

GSK 1Q Core Operating Profit GBP2.53B

30. Apr. 2025, 06:02 UTC

Ergebnisse

GSK 1Q Net Pft GBP1.62B

30. Apr. 2025, 06:01 UTC

Ergebnisse

GSK Backs 2025 View

30. Apr. 2025, 06:00 UTC

Ergebnisse

Analysts Saw GSK PLC 1Q Net Profit at GBP1.67B

30. Apr. 2025, 06:00 UTC

Ergebnisse

Analysts Saw GSK PLC 1Q Turnover at GBP7.42B

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q EPS 39.3p

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q Adj EPS 44.9p

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q Pre-items, Pretax Pft GBP2.43B

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q Oper Pft GBP2.22B

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q Net Pft GBP1.62B

30. Apr. 2025, 06:00 UTC

Ergebnisse

GSK PLC 1Q Pretax Pft GBP2.11B

Peer-Vergleich

Kursveränderung

GlaxoSmithKline PLC Prognose

Kursziel

By TipRanks

2.96% Vorteil

12-Monats-Prognose

Durchschnitt 1,400.3 GBX  2.96%

Hoch 2,290 GBX

Tief 13.55 GBX

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für GlaxoSmithKline PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

13 ratings

2

Buy

7

Halten

4

Sell

Stimmung

By Acuity

150 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.